Research programme: osteoporosis therapeutics - Galapagos/Genentech
Latest Information Update: 12 Mar 2008
At a glance
- Originator Genentech; ProSkelia
- Class Small molecules
- Mechanism of Action Integrin inhibitors; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
- 21 Feb 2003 Preclinical trials in Osteoporosis in USA (PO)
- 21 Feb 2003 Preclinical trials in Osteoporosis in Europe (PO)